SynthesisClinical and experimental medicine2025
Association between inflammatory bowel disease and the risk of liver cancer: a systematic review and meta-analysis.
Synthesis in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several studies have reported a correlation between inflammatory bowel disease (IBD) and an elevated risk of various cancers. However, the relationship between IBD and the incidence of liver cancer remains inconclusive. To address this issue, we conducted a meta-analysis to examine the association between IBD and the risk of liver cancer. A systematic search of the Cochrane Library, Embase, Web of Science, and PubMed databases was performed to identify relevant studies published up to December 22, 2024. Our meta-analysis included nine cohort studies, comprising a total of 7,305,655 participants. The pooled results indicated that patients with IBD had an increased risk of developing liver cancer (RR = 1.80; 95% CI: 1.21-2.68; p < 0.0001). An elevated risk was also observed among patients with Crohn's disease (CD) (RR = 1.78; 95% CI: 1.21-2.62), although this result did not reach statistical significance (p = 0.0972). Additionally, female IBD patients (RR = 2.47; 95% CI: 1.35-4.54; p = 0.0442) exhibited a significantly higher risk of liver cancer compared to male patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.